Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 2/20 | 0.44 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515401 | 0.97 | TRIM24 (0.47) | TRIM24TRIM33ALDH1A1MEN1CYP2C9 | |
| SCHEMBL515266 | 0.97 | TRIM24 (0.47) | TRIM24TRIM33ALDH1A1MEN1CYP2C9 | |
| SCHEMBL5110848 | 0.94 | TRIM24 (0.44) | TRIM24TRIM33ALDH1A1MEN1CYP2C9 | |
| SCHEMBL515798 | 0.92 | TRIM24 (0.50) | TRIM24TRIM33ALDH1A1MEN1CYP2C9 | |
| SCHEMBL515936 | 0.92 | TRIM24 (0.50) | TRIM24TRIM33ALDH1A1MEN1CYP2C9 | |
| SCHEMBL10051485 | 0.92 | TRIM24 (0.50) | TRIM24TRIM33ALDH1A1MEN1CYP2C9 | |
| SCHEMBL15422328 | 0.92 | TRIM24 (0.58) | TRIM24TRIM33ALDH1A1MEN1CYP2C9 | |
| SCHEMBL9171769 | 0.90 | TRIM24 (0.44) | TRIM24TRIM33ALDH1A1MEN1CYP2C9 | |
| SCHEMBL16099106 | 0.87 | TRIM24 (0.41) | TRIM24TRIM33ALDH1A1MEN1CYP2C9 | |
| SCHEMBL307414 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11359162-B2 | Spirooxathiolanone compounds, their preparation method as well as their use in perfume-making and aromatics | V. MANE FILS (FR) | 2022-06-14 | — | — | US | claimed |
| EP-3743415-B1 | NEW SPIROOXATHIOLANONE COMPOUNDS, PROCESS FOR PREPARATION THEREOF, AND USE THEREOF IN THE PERFUMERY AND AROMATICS INDUSTRY | V MANE FILS (FR) | 2022-02-16 | — | — | EP | claimed |
| US-20210032563-A1 | NEW SPIROOXATHIOLANONE COMPOUNDS, THEIR PREPARATION METHOD AS WELL AS THEIR USE IN PERFUME-MAKING AND AROMATICS | V. MANE FILS (FR) | 2021-02-04 | — | — | US | claimed |
| EP-3743415-A1 | NEW SPIROOXATHIOLANONE COMPOUNDS, PROCESS FOR PREPARATION THEREOF, AND USE THEREOF IN THE PERFUMERY AND AROMATICS INDUSTRY | V. Mane Fils (FR) | 2020-12-02 | — | — | EP | claimed |
| WO-2019145347-A1 | NEW SPIROOXATHIOLANONE COMPOUNDS, PROCESS FOR PREPARATION THEREOF, AND USE THEREOF IN THE PERFUMERY AND AROMATICS INDUSTRY | V. MANE FILS (FR) | 2019-08-01 | — | — | WO | claimed |
| EP-4683912-A1 | SUBSTITUTED THIOPHENE FUSED CYCLOHEXANONE DERIVATIVES, COMPOSITIONS COMPRISING THE SAME AND THEIR USE AS PHARMACEUTICALS | Neurasic Therapeutics Inc. (CA) | 2026-01-28 | — | — | EP | disclosed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-05-29 | — | — | US | disclosed |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| WO-2025035205-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A SUBSTITUTED THIOPHENE FUSED CYCLOHEXANONE DERIVATIVE AND A CYCLOOXYGENASE (COX) INHIBITOR, AND THEIR USE FOR THE TREATMENT OF PAIN | NEURASIC THERAPEUTICS INC. (CA) | 2025-02-20 | — | — | WO | disclosed |
| WO-2025030163-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-02-06 | — | — | WO | disclosed |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2025-01-16 | — | — | US | disclosed |
| WO-2005070407-A1 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005070898-A1 | SUBSTITUTED N-CYCLOHEXYL IMIDAZOLINONES HAVING AN MCH-MODULATORY EFFECT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-08-04 | — | — | WO | disclosed |
| EP-1445266-A2 | Photoresist copolymer | Daicel Chemical Industries, Ltd. (JP) | 2004-08-11 | — | — | EP | disclosed |
| US-20030180662-A1 | Acid-sensitive compound and resin composition for photoresist | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1000924-A1 | ACID-SENSITIVE COMPOUND AND RESIN COMPOSITION FOR PHOTORESIST | Daichel Chemical Industries Ltd (JP) | 2000-05-17 | — | — | EP | disclosed |
| US-4814450-A | CENTRAL NERVOUS SYSTEM DISORDERS | CIBA-GEIGY CORPORATION (US) | 1989-03-21 | — | — | US | disclosed |
| US-4740512-A | Treating anxiety with certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives | CIBA-GEIGY CORPORATION (US) | 1988-04-26 | — | — | US | disclosed |
| US-4647566-A | Certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives in treating anxiety | CIBA-GEIGY CORPORATION (US) | 1987-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11359162-B2 | Spirooxathiolanone compounds, their preparation method as well as their use in perfume-making and aromatics | PLK3, PAOX, HSD17B7 | TRIM24 3931/4885TRIM33 3499/4885ALDH1A1 468/4885 |
| US-20210032563-A1 | NEW SPIROOXATHIOLANONE COMPOUNDS, THEIR PREPARATION METHOD AS WELL AS THEIR USE IN PERFUME-MAKING AND AROMATICS | PLK3, PAOX, PCSK6 | TRIM24 4094/4885TRIM33 3317/4885ALDH1A1 482/4885 |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | TRIM24 1426/4885TRIM33 2750/4885ALDH1A1 4238/4885 |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | TRIM24 1756/4885TRIM33 3102/4885ALDH1A1 4457/4885 |
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | IGF1R, TRHR, TSHR | TRIM24 1244/4885TRIM33 1406/4885ALDH1A1 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.